Long title
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
Date receipt dossier
EudraCT number
2024-511168-10
Company / Sponsor
Kyverna Therapeutics, Inc.
Phase
II
Treated organism
Humans
Indication category
Immune disease
Disease
Multiple Sclerosis
Therapeutic approach
Immunotherapy
Genetic modification
CD19 CAR
Method of transfer of nucleic acid of interest
Lentiviral vector
Administered biological material
Autologous T cells transduced with lentiviral vectors expressing CD19-CAR
Route of administration
Intravenous
Locations in Belgium
UZ Antwerpen
Foreseen duration
May 2024-31 May 2027
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
KYV-101